C12Y 304/24069
Bontoxilysin , i.e. botulinum neurotoxin
Official title: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
C12Y304/24069 (Bontoxilysin , i.e. botulinum neurotoxin) appears on 403 US grants and 752 published applications in this corpus.
Search patents in C12Y- Granted patents
- 403
- Published applications
- 752
- Assignees
- 149
- Inventors
- 664
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 0 | 1 |
| 2002 | 2 | 2 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 11 |
| 2006 | 1 | 15 |
| 2007 | 5 | 15 |
| 2008 | 7 | 14 |
| 2009 | 2 | 16 |
| 2010 | 10 | 21 |
| 2011 | 11 | 20 |
| 2012 | 16 | 32 |
| 2013 | 18 | 24 |
| 2014 | 21 | 30 |
| 2015 | 37 | 47 |
| 2016 | 31 | 52 |
| 2017 | 22 | 53 |
| 2018 | 32 | 37 |
| 2019 | 28 | 43 |
| 2020 | 32 | 46 |
| 2021 | 33 | 46 |
| 2022 | 29 | 49 |
| 2023 | 11 | 42 |
| 2024 | 21 | 55 |
| 2025 | 15 | 47 |
| 2026 | 19 | 33 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect15 Sep 2026US 12,734,226 B2Revance Therapeutics, Inc.
- Treatment of brain damage18 Aug 2026US 12,708,661 B2Ipsen Biopharm Ltd.
- Evolved botulinum neurotoxins and uses thereof16 Jun 2026US 12,655,182 B2President and Fellows of Harvard College
- Therapeutic and cosmetic uses of botulinum neurotoxin serotype E2 Jun 2026US 12,642,842 B2Ipsen Biopharm Ltd.
- Methods, compositions, and devices for drug / live cell microarrays19 May 2026US 12,629,345 B2Pathak Holdings LLC
- Injection paradigm for administration of botulinum toxins24 Sep 2026US 2026/0284158 A1Allergan, Inc.
- Injection paradigm for administration of botulinum toxins24 Sep 2026US 2026/0284159 A1Allergan, Inc.
- Engineered type e botulinum neurotoxin for therapeutic and cosmetic applications17 Sep 2026US 2026/0275322 A1The Regents of the University of California
- Injection paradigm for administration of botulinum toxins10 Sep 2026US 2026/0263571 A1Allergan, Inc.
- Improved method of purifying botulinum toxin using multimodal chromatography10 Sep 2026US 2026/0265722 A1
Most cited
By later US patents
- Systems and methods for delivery of a therapeutic agent105US 7,608,275 B2The Foundry, LLC · 2009
- Methods and systems for toxin delivery to the nasal cavity98US 7,655,243 B2The Foundry, LLC · 2010
- Methods and systems for toxin delivery to the nasal cavity84US 8,105,817 B2The Foundry, LLC · 2012
- Methods for treating heart arrhythmia62US 8,948,865 B2Medtronic Ardian Luxembourg S.a.r.l. · 2015
- Method and compositions for the treatment of cerebral palsy60US 6,448,231 B2Allergan, Inc. · 2002